354 related articles for article (PubMed ID: 33103497)
1. Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities.
Shawky AM; Ibrahim NA; Abourehab MAS; Abdalla AN; Gouda AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):15-33. PubMed ID: 33103497
[TBL] [Abstract][Full Text] [Related]
2. Ethyl benzoate bearing pyrrolizine/indolizine moieties: Design, synthesis and biological evaluation of anti-inflammatory and cytotoxic activities.
Attalah KM; Abdalla AN; Aslam A; Ahmed M; Abourehab MAS; ElSawy NA; Gouda AM
Bioorg Chem; 2020 Jan; 94():103371. PubMed ID: 31708230
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
4. Discovery of nitroaryl urea derivatives with antiproliferative properties.
Wróbel TM; Kiełbus M; Kaczor AA; Kryštof V; Karczmarzyk Z; Wysocki W; Fruziński A; Król SK; Grabarska A; Stepulak A; Matosiuk D
J Enzyme Inhib Med Chem; 2016 Aug; 31(4):608-18. PubMed ID: 26114307
[TBL] [Abstract][Full Text] [Related]
5. A study on MAPK/ERK and CDK2-Cyclin-E signal switch "on and off" in cell proliferation by bis urea derivatives of 1, 4-Diisocyanatobenzene.
Nagalakshmamma V; Venkataswamy M; Pasala C; Uma Maheswari A; Thyaga Raju K; Nagaraju C; Chalapathi PV
Bioorg Chem; 2021 Jul; 112():104940. PubMed ID: 33965780
[TBL] [Abstract][Full Text] [Related]
6. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
9. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.
Türe A; Kahraman DC; Cetin-Atalay R; Helvacıoğlu S; Charehsaz M; Küçükgüzel İ
Comput Biol Chem; 2019 Feb; 78():227-241. PubMed ID: 30579980
[TBL] [Abstract][Full Text] [Related]
11. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
13. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
[TBL] [Abstract][Full Text] [Related]
14. Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity.
El-Sattar NEAA; Badawy EHK; AbdEl-Hady WH; Abo-Alkasem MI; Mandour AA; Ismail NSM
Chem Pharm Bull (Tokyo); 2021; 69(1):106-117. PubMed ID: 33390512
[TBL] [Abstract][Full Text] [Related]
15. Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening.
Elkamhawy A; Ammar UM; Paik S; Abdellattif MH; Elsherbeny MH; Lee K; Roh EJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500757
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel tranilast analogs: Docking, antiproliferative evaluation and in-silico screening of TGFβR1 inhibitors.
Ismail MMF; El-Zahabi HSA; Ibrahim RS; Mehany ABM
Bioorg Chem; 2020 Dec; 105():104368. PubMed ID: 33091671
[TBL] [Abstract][Full Text] [Related]
17. Novel pyrrolizines bearing 3,4,5-trimethoxyphenyl moiety: design, synthesis, molecular docking, and biological evaluation as potential multi-target cytotoxic agents.
Shawky AM; Ibrahim NA; Abdalla AN; Abourehab MAS; Gouda AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1313-1333. PubMed ID: 34154478
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2.
Abou-Seri SM; Eissa AAM; Behery MGM; Omar FA
Bioorg Chem; 2021 Nov; 116():105334. PubMed ID: 34534755
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
[TBL] [Abstract][Full Text] [Related]
20. Pyrrolizines: Design, synthesis, anticancer evaluation and investigation of the potential mechanism of action.
Gouda AM; Abdelazeem AH; Omar HA; Abdalla AN; Abourehab MAS; Ali HI
Bioorg Med Chem; 2017 Oct; 25(20):5637-5651. PubMed ID: 28916158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
